• LAST PRICE
    9.4100
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    8.3900/ 5
  • Ask / Lots
    10.9900/ 1
  • Open / Previous Close
    0.0000 / 9.4100
  • Day Range
    ---
  • 52 Week Range
    Low 3.8100
    High 17.7000
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 9.16
TimeVolumeIGMS
09:32 ET31379.135
09:34 ET3009.1955
09:36 ET1009.15
09:38 ET41749.2
09:41 ET4009.205
09:43 ET1009.2
09:45 ET1009.17
09:48 ET9809.3199
09:50 ET1009.25
09:52 ET10009.17
09:59 ET2009.1
10:01 ET1009.09
10:03 ET1009.06
10:08 ET3009.105
10:10 ET3009.06
10:12 ET2009.005
10:17 ET8749.0775
10:19 ET4729.066
10:24 ET1009.06
10:26 ET7009.055
10:30 ET4009.06
10:32 ET18109.045
10:35 ET4009.095
10:37 ET3009.15
10:42 ET2009.14
10:46 ET2009.17
10:50 ET1009.16
10:51 ET7259.13
10:53 ET3019.12
10:57 ET1009.07
11:00 ET1009.15
11:02 ET1009.03
11:06 ET11009.15
11:08 ET1629.11
11:09 ET2009.16
11:11 ET5009.21
11:18 ET5909.25
11:20 ET6299.26
11:22 ET23099.32
11:24 ET10449.315
11:26 ET8519.35
11:33 ET3039.4199
11:36 ET9939.35
11:38 ET1009.405
11:40 ET4009.36
11:45 ET18869.32
11:49 ET6009.28
11:56 ET3009.31
12:00 ET50759.24
12:02 ET18149.26
12:03 ET13869.27
12:05 ET7009.31
12:09 ET3839.31
12:12 ET9309.295
12:27 ET15329.28
12:30 ET9009.29
12:34 ET3009.27
12:39 ET3009.22
12:43 ET1009.24
12:45 ET7009.23
12:48 ET1009.21
12:50 ET3009.23
12:52 ET1009.175
12:54 ET18009.25
12:56 ET6009.29
12:57 ET3009.31
12:59 ET1009.35
01:03 ET3009.2801
01:12 ET19009.32
01:14 ET1009.38
01:21 ET1009.38
01:26 ET2009.3634
01:30 ET2009.4
01:32 ET7009.41
01:33 ET3439.46
01:37 ET17749.47
01:39 ET1009.47
01:44 ET1009.4495
01:46 ET4009.5
01:55 ET9009.505
02:00 ET5009.545
02:02 ET17359.58
02:04 ET4009.58
02:06 ET1009.58
02:08 ET1009.5901
02:09 ET2349.59
02:13 ET16009.59
02:15 ET16009.59
02:18 ET34879.67
02:20 ET17609.6735
02:22 ET8419.7452
02:24 ET8049.73
02:26 ET19489.675
02:27 ET2009.6457
02:29 ET5009.67
02:31 ET3009.64
02:33 ET3009.68
02:36 ET22049.61
02:38 ET3009.58
02:40 ET65649.545
02:42 ET10009.575
02:44 ET3009.55
02:45 ET4429.54
02:47 ET2009.49
02:49 ET4009.48
02:51 ET12289.555
02:54 ET8009.65
02:56 ET12709.77
02:58 ET9009.77
03:00 ET48399.57
03:09 ET6489.57
03:12 ET9979.495
03:14 ET4009.48
03:18 ET4009.4
03:20 ET12009.46
03:21 ET1009.42
03:25 ET1009.4
03:27 ET5069.4
03:30 ET8029.32
03:32 ET14679.3
03:36 ET4579.278
03:39 ET2009.26
03:41 ET20609.31
03:43 ET17459.41
03:45 ET4659.43
03:48 ET17439.48
03:50 ET8309.49
03:52 ET28649.48
03:54 ET7359.44
03:56 ET15009.44
03:57 ET14079.44
03:59 ET252259.41
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesIGMS
IGM Biosciences Inc
553.2M
-2.0x
---
United StatesCELC
Celcuity Inc
550.9M
-6.7x
---
United StatesOCS
Oculis Holding AG
501.0M
0.0x
---
United StatesSLRN
ACELYRIN Inc
543.0M
-0.5x
---
United StatesCMPS
Compass Pathways PLC
568.6M
-3.5x
---
United StatesALT
Altimmune Inc
535.3M
-4.6x
---
As of 2024-04-16

Company Information

IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.

Contact Information

Headquarters
325 E Middlefield RdMOUNTAIN VIEW, CA, United States 94043-4003
Phone
650-965-7873
Fax
302-655-5049

Executives

Chief Executive Officer, Director
Fred Schwarzer
Chief Financial Officer
Misbah Tahir
Chief Scientific Officer
Bruce Keyt
Chief Business Officer
Lisa Decker
Chief Commercial Officer
George Gauthier

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$553.2M
Revenue (TTM)
$2.1M
Shares Outstanding
58.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.26
EPS
$-4.81
Book Value
$3.46
P/E Ratio
-2.0x
Price/Sales (TTM)
259.7
Price/Cash Flow (TTM)
---
Operating Margin
-12,369.06%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.